FilingReader Intelligence
China National Medicines revenue rises 3.5% despite profit drop
August 20, 2025 at 10:41 AM UTC•By FilingReader AI
China National Medicines Corp reported revenue of 25.63 billion yuan for the first half of 2025, up 3.54%, while net profit attributable to shareholders fell 5.19%.
The company also announced the retirement of deputy general manager Ye Tong.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Sinopharm group company limited 2025 semi-annual report summaryAugust 20, 2025 at 08:00 AM UTC
Announcement of resolutions from the 28th meeting of the 8th board of directors of Sinopharm Group Co., Ltd.August 20, 2025 at 08:00 AM UTC
Sinopharm group co., ltd. special report on the deposit and actual use of raised funds for the first half of 2025August 20, 2025 at 08:00 AM UTC
Interim 2025-028 Sinopharm Group Co., Ltd. special report on the deposit and actual use of raised funds for the first half of 2025August 20, 2025 at 08:00 AM UTC
Sinopharm Group Pharmaceutical Co., Ltd.'s report on the continuous risk assessment of Sinopharm Group Finance Co., Ltd. for the first half of 2025August 20, 2025 at 08:00 AM UTC
China National Pharmaceutical Group Corporation (Sinopharm) announcement regarding the departure of senior management personnelAugust 20, 2025 at 08:00 AM UTC
SSE:600511•Shanghai Stock Exchange
News Alerts
Get instant email alerts when China National Medicines Corp publishes news
Free account required • Unsubscribe anytime